Clinical trials are vital in developing and evaluating new treatments for children with rheumatologic diseases.
Studies currently being conducted by the PRCSG include:
| Title |
Sponsor |
| A Long-term, Multicenter, Longitudinal Post-marketing, Observational Registry to Assess Long Term Safety and Effectiveness of Humira (adalimumab) in Children with Moderate to Severe Active Polyarticular or Polyarticular Course Juvenile Idiopathic Arthritis (JIA) - STRIVE |
AbbVie |
| An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis |
Bristol-Myers Squibb |
| A Phase 3 Multi-center, Open-Label Study to Evaluate Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents with Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to biologic or non biologic Disease Modifying Anti-rheumatic Drugs |
Bristol-Myers Squibb |
| A Multicenter, Open-Label Trial of Intravenous Golimumab, a Human Anti-TNFα Antibody, in Pediatric Subjects With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy |
Janssen Research & Development, LLC |
| A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus |
GlaxoSmithKline |
| A Phase I pharmacokinectic and safety study of tocilizumab (TCZ) in patients less than 2 years old with active systemic juvenile idiopathic arthritis (sJIA) |
Hoffman-La Roche |
| A Study of Intravenous MabThera/Rituxan in Pediatric Patients With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis |
Hoffman-La Roche / Genentech |
| A Randomized, Placebo-Controlled Study to Evaluate the Effect of Tocilizumab on Disease Response in Patients With Active Systemic Juvenile Idiopathic Arthritis, With an Open-Label Extension to Examine the Long Term Use of Tocilizumab |
Hoffman- La Roche |
| A study of Subcutaneously Administered RoActemra/Actemra (Tocilizumab) in Patients with Systemic Juvenile Idiopathic Arthritis |
Hoffman- La Roche |
| A study of Subcutaneously Administered RoActemra/Actemra (Tocilizumab) in Patients with Polyarticular-course Juvenile Idiopathic Arthritis |
Hoffman-La Roche |
| A study to evaluate decreased dose frequency in patients with active Systemic Juvenile Idiopathic Arthritis (SJIA) who experience laboratory abnormalities during treatment with tocilizumab |
Hoffman-La Roche |
| Long-Term extension study to evaluate the safety and efficacy of subcutaneous tocilizumab in patient with polyarticular-course and systemic juvenile idiopathic arthritis |
Hoffman-La Roche |
| An open label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestation |
Novartis Pharmaceuticals |
| A Long-term, Open-label Follow-up Study Of Cp-690,550 For Treatment Of Juvenile Idiopathic Arthritis (Jia) |
Pfizer |
| Efficacy, Safety And Tolerability Of Tofacitinib For Treatment Of Polyarticular Course Juvenile Idiopathic Arthritis (Jia) In Children And Adolescent Subjects |
Pfizer |
| Pediatric Arthritis Study of Certolizumab Pegol (PASCAL) |
UBC, Inc |
